Every 8-K that Shattuck Labs, Inc. (STTK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.
Shattuck Labs, Inc. reported second quarter 2026 results and development updates for its DR3-targeted antibody pipeline. The company had $208.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, supported by an $86.2 million underwritten offering and $57.1 million of warrant exercise proceeds, and expects this capital to fund operations into 2029.
For the quarter, Shattuck recorded no revenue, research and development expenses of $11.7 million, general and administrative expenses of $4.5 million, and a net loss of $15.2 million, or $0.12 per share. Phase 1 data for lead antibody SL-325 showed a favorable safety and immunogenicity profile and durable DR3 blockade, with a Phase 2b Crohn’s disease trial expected to start in the third quarter of 2026. Bispecific candidate SL-846 is in IND-enabling GLP toxicology studies, with initial Phase 1 data planned for 2027.
Shattuck Labs, Inc. entered into an underwriting agreement for a public offering of 10,879,376 shares of common stock at $4.00 per share and, in lieu of common stock for certain investors, pre-funded warrants to purchase 7,870,624 shares at $3.9999 per warrant. The company also granted underwriters a 30-day option to buy up to 2,812,500 additional shares, which was exercised in full on June 10, 2026. The securities are being issued under an effective shelf registration statement, with the offering expected to close on June 11, 2026. Pre-funded warrants are immediately exercisable but include beneficial ownership limits between 4.99% and 19.99% depending on holder elections.
Shattuck Labs reported encouraging Phase 1 results for SL-325, its lead DR3 blocking antibody, and a major cash influx from warrant exercises. The first-in-human trial in 72 healthy volunteers showed SL-325 was well tolerated across single and multiple ascending doses, with durable DR3 receptor occupancy, no evidence of agonist activity, and a low anti-drug antibody rate of 3.7%.
The company plans to start the RECEPTIVE-CD1 randomized Phase 2b trial of SL-325 in moderate-to-severe Crohn’s disease in the third quarter of 2026 and target 12-week induction data in the first half of 2028. Shattuck also highlighted SL-846, a DR3 x IL-23R bispecific antibody now in IND-enabling toxicology studies, with Phase 1 initiation expected in the first half of 2027.
Financially, Shattuck has received or expects to receive aggregate gross proceeds of approximately $54.9 million from the exercise of about 50.6 million common stock warrants, representing roughly 96% of warrants issued in an August 4, 2025 private placement. Combined with approximately $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, the company now expects to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan to increase the shares available for issuance by 1,691,082 and extend the plan’s term to March 23, 2036.
As of the April 2, 2026 record date, 75,581,787 shares of common stock were entitled to vote. All three Class III director nominees were elected, KPMG LLP was ratified as independent auditor, and the advisory vote on executive compensation passed. Stockholders favored holding future say‑on‑pay votes every year, and the company plans to conduct these votes annually.
Shattuck Labs, Inc. reported first quarter 2026 results and business updates. The company is running a Phase 1 trial of its lead DR3 blocking antibody SL-325, has completed enrollment in all single- and multiple-ascending dose cohorts, and plans to share detailed data in the second quarter of 2026. Subject to positive Phase 1 data and regulatory alignment, a Phase 2 trial in Crohn’s disease is expected to start in the third quarter of 2026, and a lead DR3-based bispecific antibody has entered IND-enabling activities.
Financially, Shattuck had $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, up from $60.9 million a year earlier. First quarter 2026 research and development expenses were $10.9 million, general and administrative expenses were $4.6 million, and net loss was $14.8 million, or $(0.13) per basic and diluted share. The company expects existing cash, including potential proceeds from outstanding common stock warrants, to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. reported fourth quarter and full-year 2025 results and updated its development and cash outlook. The company is advancing SL-325, a potential first-in-class DR3 blocking antibody, with Phase 1 data expected in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.
R&D expenses fell to $35.3 million in 2025 from $67.2 million in 2024, mainly due to discontinuation of the SL-172154 program and workforce reductions, while G&A decreased to $17.2 million from $19.1 million. Net loss narrowed to $48.8 million, or $0.70 per share, from $75.4 million, or $1.49 per share, in the prior year.
Cash, cash equivalents and short-term investments were approximately $78.1 million as of December 31, 2025, and about $94.5 million as of February 28, 2026 including $21.4 million of gross proceeds from at-the-market stock sales. Based on current plans and assuming full warrant exercise, Shattuck expects its capital to fund operations into 2029.
Shattuck Labs, Inc. has set its 2026 annual meeting of stockholders for Thursday, May 28, 2026. The meeting date is more than 30 days earlier than the prior year’s meeting, so previously disclosed deadlines for stockholder proposals and director nominations no longer apply.
The company will provide revised deadlines in connection with the 2026 annual meeting, and any stockholder proposals or nominations must comply with SEC Rule 14a-8 and the company’s Bylaws. Full details will appear in upcoming proxy materials to be filed with the SEC.
Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to sell up to $75,000,000 of its common stock through an at-the-market equity program under an effective Form S-3 shelf registration. Shares may be sold from time to time at market prices, and the company is not obligated to sell any amount and can suspend or terminate the program.
Leerink Partners will act as sales agent and earn a commission of up to 3.0% of the gross sales price of any shares sold, plus reimbursed expenses. Shattuck Labs plans to use any net proceeds to fund ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.
Shattuck Labs (STTK) filed an 8-K/A (Amendment No. 1) to correct typographical errors in a previously filed 8-K. The amendment covers Item 2.02 relating to a press release announcing financial results for the quarter ended September 30, 2025, which is furnished as Exhibit 99.1.
The company notes that, under General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed. The filing also lists Exhibit 104, the cover page formatted in Inline XBRL.
Shattuck Labs (STTK) furnished an update under Item 2.02, announcing it issued a press release with financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under General Instruction B.2, meaning it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Shattuck Labs, Inc. (STTK) filed a Form 8-K reporting board-related governance updates. The filing notes a Non-Employee Director Compensation Policy and states that Dr. Baker and Dr. Ashiya intend to enter the company’s standard form of indemnification agreement. The agreement for Dr. Ashiya will be modified to reflect her status as an OrbiMed Designee, as defined in the filing. The 8-K references a press release dated August 26, 2025 and also confirms that the 8-K, including the press release attached as Exhibit 99.1, will not be deemed incorporated by reference into filings under the Exchange Act or the Securities Act.
Shattuck Labs, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The 8-K states the press release is provided as Exhibit 99.1 and clarifies that the information is furnished (not "filed") for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except by specific reference. The filing confirms the company trades as STTK on The Nasdaq Global Select Market and that it is designated as an emerging growth company.
The 8-K contains no financial figures or discussion of results within the form itself and provides an exhibit listing and signature by CEO Dr. Taylor Schreiber. No additional operational or transaction details are included in this report.